Analysis Prevents Manufacturer from Launching Problematic Program
| Industry | Pharmaceutical Manufacturer |
| Problem | A major brand pharmaceutical manufacturer was considering launching an educational and incentive program but faced operational challenges introducing the program. |
| PHSI Solution | After reviewing the manufacturer’s draft communication pieces for the program, PHSI found the content unclear and confusing. The drafts left out pertinent information such as which prescriptions qualified for the program and how patients were to obtain incentives. Instructions to the pharmacist failed to adequately explain billing procedures. |
| Results | PHSI’s testing uncovered critical issues with the program that led to the manufacturer’s decision to not launch the program. Had the program been launched, the manufacturer would have faced patient and pharmacist complaints and would have wasted significant resources on an unsuccessful program. |
Poll Results
August 2023 Question of the Month
What steps do you take when learning about an electronic prescribing challenge?
Root cause analysis: 0%
Compendia review: 0%
Engage a partner: 0%
All of the above: 50%
None of the above: 50%
July 2023 Question of the Month
Does your organization have a strategy for Humira biosimilar launches?
Yes, well defined: 0%
We have a framework: 50%
Waiting for clarity: 0%
No: 0%
Unaware of need: 50%
June 2023 Question of the Month
How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?
During Phase II Trials: 0%
Initiation of Phase III Trials: 66%
6 months prior to approval: 33%
3 months prior to approval: 0%
At time of approval: 0%
After approval: 0%
No strategy: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
